New Clinical Trial to Uncover How Anti-Obesity Drugs Affect Energy Metabolism
Background
Obesity is a global health crisis linked to numerous comorbidities like type 2 diabetes and cardiovascular disease. While anti-obesity medications (AOMs) like Semaglutide and Tirzepatide have shown significant efficacy in weight loss, their precise, long-term impact on the body's fundamental energy metabolism and body composition remains less understood. This study addresses the crucial knowledge gap regarding how these medications specifically alter 24-hour energy expenditure and substrate oxidation over time.
Study Design
Results
As a prospective study, this research is currently NOT_YET_RECRUITING and therefore has no findings to report. However, it is designed to rigorously quantify the long-term effects of anti-obesity medications. The primary objective is to measure changes in 24-hour energy expenditure and substrate oxidation (how the body uses fats vs. carbohydrates for energy) in patients receiving treatment. Researchers will also assess alterations in body composition using Dual-energy X-ray absorptiometry (DXA), specifically looking at fat mass and lean mass distribution. The study's central goal is to precisely determine how Semaglutide and Tirzepatide impact the body's overall energy metabolism and body composition over an extended treatment period in individuals with obesity.
Why It Matters
Understanding the specific metabolic shifts induced by Semaglutide and Tirzepatide is crucial for optimizing obesity treatment strategies. If the study reveals significant, sustained improvements in energy expenditure or favorable changes in substrate oxidation, it could provide deeper insights into the mechanisms behind weight loss and maintenance. This knowledge could help tailor treatments, predict patient responses, and potentially lead to more personalized and effective clinical use of these powerful anti-obesity drugs. The findings could also inform future drug development targeting specific metabolic pathways.